BioLineRx (BLRX) Accumulated Expenses (2016 - 2020)

BioLineRx's Accumulated Expenses history runs 5 years deep, the most recent figure standing at $287000.0 for Q4 2020.

• On a quarterly basis, Accumulated Expenses fell 60.52% year-over-year to $287000.0 in Q4 2020; TTM through Dec 2020 was $287000.0, a 60.52% decrease from a year earlier, with the FY2020 full-year figure at $287000.0, down 60.52% from the prior year.
• Accumulated Expenses retreated to $287000.0 in Q4 2020 per BLRX's latest filing, from $727000.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $792000.0 in Q4 2018 and bottomed at $215000.0 in Q4 2017.
• The 5-year median for Accumulated Expenses is $560000.0 (2016), against an average of $516200.0.
• Across the five-year window, Accumulated Expenses sank 61.61% in 2017 and surged 268.37% in 2018, its largest moves.
• Year by year, Accumulated Expenses stood at $560000.0 in 2016, then sank by 61.61% to $215000.0 in 2017, then jumped by 268.37% to $792000.0 in 2018, then declined by 8.21% to $727000.0 in 2019, then sank by 60.52% to $287000.0 in 2020.
• Per Business Quant, the three latest BLRX Accumulated Expenses figures stand at $287000.0 (Q4 2020), $727000.0 (Q4 2019), and $792000.0 (Q4 2018).